OBJECTIVES: Very early-onset inflammatory bowel disease (VEO-IBD) arises in children less than 6 years old, a critical time for immunologic development and maturation of the intestinal microbiome. Non-conventional lymphocytes, defined here as mucosal-associated invariant T cells and innate lymphocytes, require microbial products for either development or expansion, aspects that could be altered in very early-onset inflammatory bowel disease. Our objective was to define conventional leukocyte and non-conventional lymphocyte populations in controls and patients using multiparameter flow cytometry to test the hypothesis that their frequencies would be altered in a chronic inflammatory state associated with significant dysbiosis. METHODS: Multiparameter flow cytometry was used in a control cohort of 105 subjects to define age-effects, not previously comprehensively examined for these cell types in humans. Differences were defined between 263 unique age-matched patients with VEO-IBD and 105 controls using Student t-test. Subjects were divided into two age groups at the time of sampling to control for age-related changes in immune composition. RESULTS: Intermediate monocytes were consistently decreased in patients with VEO-IBD compared to controls. Mucosal-associated invariant T cells were significantly lower in patients with long-standing disease. Levels were less than half of those seen in the age-matched control cohort. The innate lymphoid cells type 2 population was expanded in the youngest patients. CONCLUSION: Mucosal-associated invariant T cells are diminished years after presentation with inflammatory bowel disease. This durable effect of early life intestinal inflammation may have long-term consequences. Diminished mucosal-associated invariant T cells could impact host defense of intestinal infections.
OBJECTIVES: Very early-onset inflammatory bowel disease (VEO-IBD) arises in children less than 6 years old, a critical time for immunologic development and maturation of the intestinal microbiome. Non-conventional lymphocytes, defined here as mucosal-associated invariant T cells and innate lymphocytes, require microbial products for either development or expansion, aspects that could be altered in very early-onset inflammatory bowel disease. Our objective was to define conventional leukocyte and non-conventional lymphocyte populations in controls and patients using multiparameter flow cytometry to test the hypothesis that their frequencies would be altered in a chronic inflammatory state associated with significant dysbiosis. METHODS: Multiparameter flow cytometry was used in a control cohort of 105 subjects to define age-effects, not previously comprehensively examined for these cell types in humans. Differences were defined between 263 unique age-matched patients with VEO-IBD and 105 controls using Student t-test. Subjects were divided into two age groups at the time of sampling to control for age-related changes in immune composition. RESULTS: Intermediate monocytes were consistently decreased in patients with VEO-IBD compared to controls. Mucosal-associated invariant T cells were significantly lower in patients with long-standing disease. Levels were less than half of those seen in the age-matched control cohort. The innate lymphoid cells type 2 population was expanded in the youngest patients. CONCLUSION: Mucosal-associated invariant T cells are diminished years after presentation with inflammatory bowel disease. This durable effect of early life intestinal inflammation may have long-term consequences. Diminished mucosal-associated invariant T cells could impact host defense of intestinal infections.
Authors: Asama Lekbua; Jodie Ouahed; Amy E O'Connell; Stacy A Kahn; Jeffrey D Goldsmith; Toshihiko Imamura; Christine N Duncan; Judith R Kelsen; Elizabeth Worthey; Scott B Snapper; Samir Softic Journal: J Pediatr Gastroenterol Nutr Date: 2019-07 Impact factor: 2.839
Authors: Michael G Constantinides; Verena M Link; Samira Tamoutounour; Andrea C Wong; P Juliana Perez-Chaparro; Seong-Ji Han; Y Erin Chen; Kelin Li; Sepideh Farhat; Antonin Weckel; Siddharth R Krishnamurthy; Ivan Vujkovic-Cvijin; Jonathan L Linehan; Nicolas Bouladoux; E Dean Merrill; Sobhan Roy; Daniel J Cua; Erin J Adams; Avinash Bhandoola; Tiffany C Scharschmidt; Jeffrey Aubé; Michael A Fischbach; Yasmine Belkaid Journal: Science Date: 2019-10-25 Impact factor: 47.728
Authors: E I Benchimol; A Guttmann; A M Griffiths; L Rabeneck; D R Mack; H Brill; J Howard; J Guan; T To Journal: Gut Date: 2009-08-02 Impact factor: 23.059
Authors: Eunyoung Chun; Sydney Lavoie; Diogo Fonseca-Pereira; Sena Bae; Monia Michaud; Hamid R Hoveyda; Graeme L Fraser; Carey Ann Gallini Comeau; Jonathan N Glickman; Miles H Fuller; Brian T Layden; Wendy S Garrett Journal: Immunity Date: 2019-10-15 Impact factor: 31.745
Authors: Christoph Schneider; Claire E O'Leary; Jakob von Moltke; Hong-Erh Liang; Qi Yan Ang; Peter J Turnbaugh; Sridhar Radhakrishnan; Michael Pellizzon; Averil Ma; Richard M Locksley Journal: Cell Date: 2018-06-07 Impact factor: 41.582
Authors: Marianne Forkel; Sophie van Tol; Charlotte Höög; Jakob Michaëlsson; Sven Almer; Jenny Mjösberg Journal: J Crohns Colitis Date: 2019-01-01 Impact factor: 9.071